The ambitious goal of validating prognostic biomarkers for systemic sclerosis-related interstitial lung disease

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1034-1036

  Bonella, Francesco ^a   Caramaschi, Paola ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CC CHEMOKINE LIGAND 18; CHEMOKINE; IMMUNOSUPPRESSIVE AGENT; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SURVIVAL; SYSTEMIC SCLEROSIS; VALIDATION PROCESS;

CHEMOKINES, CC; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; SCLERODERMA, SYSTEMIC;

EID: 84879896028     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130549     Document Type: Review

References (20)

1. Olson AL, Brown KK, Fischer A. Connective tissue diseaseassociated lung disease. Immunol Allergy Clin North Am 2012;32:513-36.
2. Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006;33:1789-801.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
4. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
5. Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, et al. Clinically significant interstitial lung disease in limited scleroderma: Histopathology, clinical features, and survival. Chest 2008;134:601-5.
6. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009;36:773-80.
7. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger H, et al. Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
8. du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW. Idiopathic pulmonary fibrosis: Lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012;186:712-5.
9. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013;52:155-60.
10. Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol 2012;2012:121439.
11. Murray LA, Rubinowitz A, Herzog EL. Interstitial lung disease: Is interstitial lung disease the same as scleroderma lung disease? Curr Opin Rheumatol 2012;24:656-62.
12. Baraut J, Michel L, Verrecchia F, Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010;10:65-73.
13. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8:e60635.
14. Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology 2013 Apr 17. [Epub ahead of print]
15. Elhaj M, Charles J, Pedroza C, Liu X, Zhou X, Estrada YM, et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013;40:1114-20.
16. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007;56:1685-93.
17. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: A sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005;52:2889-96.
18. Tiev KP, Hua-Huy T, Kettaneh A, Gain M, Duong-Quy S, Toledano C, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011;38:1355-60.
19. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:717-23.
20. Bonella F, Volpe A, Caramaschi P, Nava C, Ferrari P, Schenk K, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: Correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:27-33.